FYR
Missoula, Montana, United States · Artificial Intelligence, Biotechnology, Health Care · 19 employees
FYR Bio (FYR Diagnostics Inc) is revolutionizing the ability to dynamically observe disease and treatment response to produce better biomarkers, trials, drugs and outcomes. FYR's EV-Omics™ (EVO) platform leverages its proprietary technology, SPARCs™, to enrich for extracellular vesicles from diseased cells and enable assessment of cellular proteins and nucleic acids with a peripheral blood sample.
Funding history
- Funding Round — $8.0M — Sep 2025
- Series pre-seed — $31K — Nov 2024
Recent signals
- Feb 10, 2026: FYR Bio Appoints Barbara K. Zehentner as Chief Operating Officer
- Sep 24, 2025: Raised $8.0M
- Nov 18, 2024: Raised $31K in Series pre-seed
See plans & pricing → Track FYR’s funding, hiring, and signals — with verified contacts — on Fundz.